Key facts
- This page summarizes Gary Ingenito's Form 4 filing for CATALYST PHARMACEUTICALS, INC. (CPRX).
- 6 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 15 May 2025, 17:00.
Gary Ingenito - 13 May 2025 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)
- Reporting relationship
- Chief Med. & Reg. Officer
- Issuer ticker
- CPRX
- Reported as of
- 13 May 2025
- Net transaction value
- -$4,887,560
- SEC form
- 4
- Accepted by SEC
- 15 May 2025, 17:00:41 UTC
- Prior SEC filing
- 07 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gary Ingenito
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Gary Ingenito filed Form 4 for CATALYST PHARMACEUTICALS, INC. (CPRX) on 15 May 2025.
Change
- Previous filing in this sequence was filed on 07 Mar 2025.
- Current net transaction value: -$4,887,560.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001279473
Primary reporting owner
INGENITO GARY
- Relationship
- Chief Med. & Reg. Officer
- Address
- 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES
- Signature
- /s/ Gary Ingenito
- Signature date
- 15 May 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CPRX
transaction
Common stock, par value $0.001 per share
Options Exercise
- Transaction value
- $684,000
- Shares
- +200,000
- Change %
- +290%
- Price
- $3.42
- Shares after
- 268,873
- Date
- 13 May 2025
- Ownership
- Direct
CPRX
transaction
Common stock, par value $0.001 per share
Sale
- Transaction value
- $4,736,000
- Shares
- -200,000
- Change %
- -74%
- Price
- $23.68
- Shares after
- 68,873
- Date
- 13 May 2025
- Ownership
- Direct
- Footnotes
- F1, F2
CPRX
transaction
Common stock, par value $0.001 per share
Options Exercise
- Transaction value
- $204,160
- Shares
- +44,000
- Change %
- +64%
- Price
- $4.64
- Shares after
- 112,873
- Date
- 14 May 2025
- Ownership
- Direct
CPRX
transaction
Common stock, par value $0.001 per share
Sale
- Transaction value
- $1,039,720
- Shares
- -44,000
- Change %
- -39%
- Price
- $23.63
- Shares after
- 68,873
- Date
- 14 May 2025
- Ownership
- Direct
- Footnotes
- F1, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CPRX
transaction
Derivative
Options to purchase common stock
Options Exercise
- Transaction value
- $0
- Shares
- -200,000
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 590,282
- Date
- 13 May 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200,000
- Exercise price
- $3.42
- Footnotes
- F4
CPRX
transaction
Derivative
Options to purchase common stock
Options Exercise
- Transaction value
- $0
- Shares
- -44,000
- Change %
- -7.5%
- Price
- $0.000000
- Shares after
- 546,282
- Date
- 14 May 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 44,000
- Exercise price
- $4.64
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.
Footnote F2
Represents a weighted average price for the shares sold. Shares were sold in a range between $23.325 and $23.93 per share.
Footnote F3
Represents a weighted average price for the shares sold. Shares were sold in a range between $23.44 and $24.025 per share.
Footnote F4
Options vested in three annual tranches beginning on December 30, 2021.
Footnote F5
Options vested in three annual tranches beginning on December 2, 2020.